Evaluation of the efficacy of biological agents used to treat Dress Syndrome refractory to corticosteroids: A scoping review
DOI:
https://doi.org/10.33448/rsd-v14i2.48230Keywords:
Drug hypersensitivity syndrome; Biological products; Drug-related side effects and adverse reactions.Abstract
Patients with Dress Syndrome often present resistance to traditional pharmacological therapies, which include the use of corticosteroids and pulse therapy. In severe and recurrent cases of this syndrome, the use of biological agents tends to be strongly recommended, allowing the prevention of possible deleterious outcomes. The present study aims to evaluate the efficacy of biological agents used for Dress Syndrome refractory to corticotherapy. For this scoping review, carried out through the PubMed and ScienceDirect platforms, between the years 2022 and 2025, the descriptors chosen were ‘’Drug Hypersensitivity Syndrome’’, ‘’Biological Products’’ and ‘’Adverse Drug Event’’. The inclusion criteria consisted of (1) Evaluation of the use and efficiency of biological agents, (2) Analysis of the management of Dress Syndrome refractory to corticosteroid therapy, (3) Studies comparing the performance of different immunobiological agents, (4) Texts addressing monitoring, follow-up and clinical management and (5) Articles in English and Portuguese. The exclusion criteria consisted of inappropriateness to the topic, case reports, editorials, studies with animals and texts outside the time limit. Patients with severe Dress who used biological agents early showed a reduction in acute lethal symptoms, as well as a reduction in the length of hospital stay and deleterious outcomes associated with high doses of corticosteroids. The studies demonstrated that compared to the elderly population, young individuals tend to have a better prognosis and therapeutic response. Recommendations regarding the interaction and discontinuation of such biological therapies are controversial topics to be elucidated through new studies.
References
Chen, X., Hu, L., Xiao, Z., Wu, H., Chen, A., & Yu, R. (2023). Características das reações adversas cutâneas a medicamentos, especialmente em relação ao período de incubação, com base em pacientes hospitalizados. Anais Brasileiros de Dermatologia (Portuguese), 98(2), 227-232.
Almeida Dornelas, D. B. (2023). Síndrome de dress, principais conceitos clínicos. Repositório de Trabalhos de Conclusão de Curso.
Melo, M. E. F., Porfiro, C. A., Dantas, L. A., Neto Filho, M. A., Triches, C. M. F., & dos Santos, J. S. G. (2022). Principais classes farmacológicas relacionadas à farmacodermia. Research, Society and Development, 11(2), e8011225492-e8011225492.
Gibson, A., Deshpande, P., Campbell, C. N., Krantz, M. S., Mukherjee, E., Mockenhaupt, M., & Phillips, E. J. (2023). Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions. Journal of Allergy and Clinical Immunology, 151(2), 289-300.
Hama, N., Abe, R., Gibson, A., & Phillips, E. J. (2022). Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): clinical features and pathogenesis. The Journal of Allergy and Clinical Immunology: In Practice, 10(5), 1155-1167.
James, F., Goh, M. S., Vogrin, S., Ng, I., Douglas, A. P., Holmes, N. E., & Trubiano, J. A. (2024). The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR)–Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions. World Allergy Organization Journal, 17(8), 100936.
Kan, A. K. C., Tang, W. T., & Li, P. H. (2024). Helper T cell subsets: Development, function and clinical role in hypersensitivity reactions in the modern perspective. Heliyon, 10(9).
Kuang, F. L., Khoury, P., Weller, P. F., Wechsler, M. E., & Klion, A. D. (2023). Biologics and hypereosinophilic syndromes: knowledge gaps and controversies. The Journal of Allergy and Clinical Immunology: In Practice, 11(9), 2666-2671.
López, E., Cabrera,R., & Lecaros, C. (2024). Anais Brasileiros de. Anais Brasileiros de Dermatologia, 99(4).
Macy, E., Trautmann, A., Chiriac, A. M., Demoly, P., & Phillips, E. J. (2023). Advances in the understanding of drug hypersensitivity: 2012 through 2022. The Journal of Allergy and Clinical Immunology: In Practice, 11(1), 80-91.
Park, B. C., Stone, C. A., Dewan, A. K., & Johnson, D. B. (2022). Hypersensitivity reactions and immune-related adverse events to immune checkpoint inhibitors: approaches, mechanisms, and models. Immunology and Allergy Clinics, 42(2), 285-305.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. UFSM.
Snyder, H. (2019). Literature review as a research methodology: An overview and guidelines. Journal of business research, 104, 333-339.
Yaytokgil, Ş. B., Selmanoglu, A., Celik, I. K., Emeksiz, Z. Ş., Ginis, T., Karaatmaca, B., & Misirlioğlu, E. D. (2024). Evaluation of the frequency and characteristics of drug hypersensitivity reactions in hospitalized children: Real life-cohort study. World Allergy Organization Journal, 17(4), 100893.
Wang, C. W., Divito, S. J., Chung, W. H., & Hung, S. I. (2022). Advances in the pathomechanisms of delayed drug hypersensitivity. Immunology and Allergy Clinics, 42(2), 357-373.
Wang, S., Kang, Y., He, C., & Jin, H. (2024). The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids. World Allergy Organization Journal, 17(8), 100935.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Trinnye Luizze Santos; Walquiria da Silva Pedra Parreira; Beatriz França Soares da Silva; Mayara Costa Manso Morais; Giovana Cavalcante de Souza; Bárbara Perini Rodrigues; Leonardo Cortes de Aguiar Franco
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
